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Movement of circulating fatty acids (FAs) to parenchymal cells requires their transfer across the endothelial cell (EC)
barrier. The multiligand receptor cluster of differentiation 36 (CD36) facilitates tissue FA uptake and is expressed in ECs and
parenchymal cells such as myocytes and adipocytes. Whether tissue uptake of FAs is dependent on EC or parenchymal cell
CD36, or both, is unknown. Using a cell-specific deletion approach, we show that EC, but not parenchymal cell, CD36 deletion
increased fasting plasma FAs and postprandial triglycerides. EC-Cd36–KO mice had reduced uptake of radiolabeled longchain FAs into heart, skeletal muscle, and brown adipose tissue; these uptake studies were replicated using [11C]palmitate
PET scans. High-fat diet–fed EC-CD36–deficient mice had improved glucose tolerance and insulin sensitivity. Both EC and
cardiomyocyte (CM) deletion of CD36 reduced heart lipid droplet accumulation after fasting, but CM deletion did not affect
heart glucose or FA uptake. Expression in the heart of several genes modulating glucose metabolism and insulin action
increased with EC-CD36 deletion but decreased with CM deletion. In conclusion, EC CD36 acts as a gatekeeper for parenchymal
cell FA uptake, with important downstream effects on glucose utilization and insulin action.

Introduction

Long-chain fatty acids (LCFAs) provide cellular energy and are precursors for membrane components and intracellular lipid stores.
Their bioactive derivatives influence gene expression and signal
transduction pathways. Distribution of LCFAs among organs, especially muscle, adipose tissue, and liver, is key to maintaining metabolic homeostasis (1). In the bloodstream, LCFAs circulate as unesterified free fatty acids (FFAs) bound to albumin or as triglyceride
(TG) and phospholipid components of lipoproteins. Tissue uptake of
LCFAs requires transfer across an endothelial cell (EC) barrier, but
the molecular events necessary for this remain unknown.
In cultured parenchymal cells, LCFA uptake occurs via a saturable receptor-mediated pathway and a nonsaturable pathway
thought to reflect passive diffusion (2, 3). Several proteins have
been implicated in facilitating LCFA accumulation, including
enzymes involved in FA acylation and the scavenger receptor cluster of differentiation 36 (CD36) (4). CD36 (also called SR-B2) is
a multifunctional protein involved in apoptotic cell uptake, signal
transduction, cellular adhesion, angiogenesis, and immune function (5). It was first linked to lipid metabolism when it was shown
to function as a macrophage receptor for oxidized LDL (6) and as
an adipocyte receptor/transporter for LCFAs (7). LCFA binding
to the CD36 ectodomain is followed by FA transfer to the plasma
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membrane through an internal tunnel that runs the length of the
protein, as shown by the crystal structure of the CD36-LCFA complex (8). CD36 also functions as a LCFA sensor, influencing activation of PPARs (9) and AMPK (10).
In mice, germline CD36 deficiency reduces acute accumulation of
LCFAs in the heart, skeletal muscle, and adipose tissues (11). Moreover,
Cd36–/– mice have increased fasting levels of FFAs (11, 12) and delayed
clearance of postprandial lipids (11–13). The defect in LCFA uptake is
also observed in CD36-deficient humans (14). Furthermore, a common
haplotype at the CD36 locus is associated with greater circulating FFA
levels (15). Whether the defect in FA uptake is consequent to reduced
CD36 expression in ECs, parenchymal cells, or both is unknown. We
bred mice with CD36 deletion specific to ECs (EC-Cd36–/–) or cardiomyocytes (CM-Cd36–/–) to determine which cell type(s) regulate organ/
tissue accumulation of LCFAs and TGs. Our data show that EC CD36 is
needed for optimal movement of LCFAs from the circulation to cardiomyocytes (CMs). LCFA uptake was also diminished in brown adipose
tissue (BAT) and skeletal muscle, but not liver, of EC-Cd36–/– mice.
Loss of EC CD36 improved glucose tolerance and insulin sensitivity
and increased glucose uptake during fasting in heart, skeletal muscle,
and white adipose tissue (WAT). The data reveal that CD36-mediated
FA transport across ECs limits tissue FA uptake and that its loss leads to
metabolic effects in parenchymal cells.

Results

CD36 is abundantly expressed in vascular ECs and CMs in human
and mouse hearts. We investigated CD36 distribution in human
and mouse heart tissues and assessed the fidelity of our cell-spejci.org   Volume 128   Number 10   October 2018
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Figure 1. CD36 distribution in human and mouse hearts and creation of
EC- and CM-Cd36–/– mice. (A) CD36 antibody staining of CMs and blood
vessel ECs from human and mouse hearts. Original magnification, ×20. (B)
Male mouse heart suborgan fractionation showing Cd36 mRNA levels in
different cell types (n = 12–18). Data represent mean ratios normalized to
CM-Cd36–/– (set at 1.0). (C) Genomic structure of murine Cd36, the targeting
vector, and the mutated allele. Gray boxes represent the numbered murine
Cd36 exons. Red arrows indicate transcription orientation. Black bent
arrows indicate the translation start site. PCR primers (blue arrows) were
chosen to differentiate between the WT genomic allele and the homologously recombined allele. (D) PCR of tail genomic DNA (using primer
1) and (E) heart tissue DNA (using primer 2) from Cd36fl/fl, EC-Cd36–/–,
and CM-Cd36–/– mice. (F) PCR product sequencing showing ablation of
exons 3 and 4 of Cd36 gene after Cre-mediated recombination. (G) Heart
Cd36 mRNA in EC-Cd36–/– and CM-Cd36–/– mice quantified by qRT-PCR
using primer 3 (n = 5–6, mean ± SD). Data are corrected for 18S rRNA and
normalized to Cd36fl/fl controls. Immunoblots show CD36 in EC-Cd36–/– and
CM-Cd36–/– mouse hearts. (H) Immunoblots of CD36 in EC-Cd36–/– muscle,
WAT, BAT, and liver. *P < 0.05, #P < 0.01 and §P < 0.001 compared with
Cd36fl/fl controls; 1-way ANOVA with Dunnett’s multiple comparisons test.

cific deletions. We found that CD36 was present in ECs and CMs
in both human and mouse hearts (Figure 1A) and that staining was
most intense in small blood vessels, weaker in larger arteries, and
absent in total Cd36 –/– mouse hearts. In WT mouse hearts subjected
to Langendorff perfusion and subsequent suborgan fractionation
using gradient density separation and FACS, we found that Cd36
mRNA levels were significantly higher in ECs than in CMs from
both male (Figure 1B) and female mice (Supplemental Figure 1A;
supplemental material available online with this article; https://
doi.org/10.1172/JCI99315DS1). ISH data showed Cd36 mRNA
expression in WT, but not total Cd36 –/–, mouse hearts, with the most
intense signals detected in capillary ECs (Supplemental Figure 1B).
CD36 mRNA and protein are specifically reduced in EC- and
CM-Cd36 –/– mouse hearts. To determine the contribution of EC
versus CM CD36 to heart FFA uptake, we created a Cd36fl/fl mouse
line (Figure 1C). We crossed Cd36fl/fl mice with Tie2-Cre mice to
generate EC-Cd36 –/– mice and with MHC-Cre mice to generate
CM-Cd36 –/– mice. Both groups were fertile and appeared normal.
We used PCR to detect Cd36fl/fl and Cd36 –/– alleles from tail (Figure 1D) and heart (Figure 1E) DNA. PCR product sequencing from
Cd36-null fragments showed ablation of exons 3 and 4 of the Cd36
gene after Cre-mediated recombination (Figure 1F). Cd36 mRNA
and protein levels were reduced by more than 50% in the hearts
of EC-Cd36 –/– mice compared with levels in Cd36fl/fl mouse hearts;
CM-Cd36 –/– mice also had an approximately 50% reduction of
Cd36 mRNA in the heart, with parallel reductions in protein content (Figure 1G). The approximately 50% reduction with either the
EC or CM KO suggests that total heart CD36 is equally divided in
these 2 cell types. EC-Cd36 –/– mice had reduced Cd36 mRNA in
skeletal muscle, BAT, and liver (Supplemental Figure 1, C–E), and
we measured parallel reductions in CD36 protein in skeletal muscle, adipose tissue (WAT and BAT), and liver (Figure 1H). Immunohistologic analysis of cardiac ventricular sections stained with
polyclonal rabbit CD36 antibody confirmed CD36 ablation specificity to capillary ECs from EC-Cd36 –/– mice (Figure 2A). These
mice had significantly reduced Cd36 levels in the lungs, which are
particularly rich in ECs (Supplemental Figure 1F). To verify that
CD36 is specifically deleted in ECs, we double stained EC-Cd36 –/–
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heart tissues with CD36 and the EC marker CD31. Both CD36 and
CD31 colocalized to capillary ECs of Cd36fl/fl control mice, while
CD36 protein was undetected in CD31-positive EC-Cd36 –/– heart
tissues (Figure 2B). We further confirmed the specificity of the
EC versus CM deletions by immunofluorescence of isolated ECs
and CMs from lung and heart tissues. We found that CMs from
EC-Cd36 –/– hearts contained normal levels of CD36 protein,
whereas CD36 was undetectable in CM-Cd36 –/– heart CMs (Figure
2C). Primary ECs isolated from the lungs of Cd36fl/fl and inducible
VE-cadherin Cd36 –/– mice (16) were stained for both VE-cadherin, an endothelium-specific molecule, and CD36 and showed
an absence of CD36 staining in VE-cadherin–positive ECs from
EC-Cd36 –/– mice (Figure 2D).
To verify that Cd36 EC deletion did not cause off-target effects,
we confirmed the presence of CD36 in CMs isolated from EC-Cd36–/–
mice and analyzed the cells by Western blotting and quantitative
real-time PCR (qRT-PCR) (Supplemental Figure 1G). These data
proved that CD36 was deleted in ECs but not parenchymal cells.
To determine whether CD36 deletion modified the metabolic
gene profile in ECs, we isolated ECs from Cd36fl/fl, EC-Cd36–/–, and
CM-Cd36–/– mouse hearts using FACS. Genes involved in glucose
metabolism were not altered significantly in ECs from the 3 groups
(Supplemental Figure 1H). We also found no changes in FA oxidation genes in ECs with CD36 deletion, consistent with glucose being
the primary substrate for ATP production in these cells. Thus, CD36
is not a major regulator of lipid or glucose metabolism in ECs.
We used laser capture microdissection (LCM) technology
to isolate CMs and determine the expression of glucose and FA
metabolism genes. Glut1 mRNA increased, while pyruvate dehydrogenase kinase 4 (Pdk4) and carnitine palmitoyl transferase 1
(Cpt1) were decreased in the EC-Cd36–/– CMs (Supplemental Figure 1I). These changes suggest a switch from FA to glucose use.
CD36 deletion in ECs increases plasma FFA and postprandial TG
levels, while decreasing plasma glucose levels and enhancing insulin sensitivity. Deletion of EC Cd36 increased fasting plasma FFAs (Figure 3A), a phenotype similar to that of mice with global CD36 deletion (12). Fasting plasma total cholesterol (TC), TGs, glycerol, and
lipoprotein lipids (Supplemental Figure 2, A–E) were unchanged
in 4-month-old male EC-Cd36 –/– mice compared with levels in
Cd36fl/fl controls. However, age-matched female EC-Cd36 –/– mice
showed decreased plasma glucose together with increased fasting
plasma TC, FFA, and TGs associated with an increase in VLDL-TG
and HDL-TC (Supplemental Figure 3, A–F). These sex differences
in lipid levels might reflect previously reported sex differences in
the regulation of tissue CD36 expression and muscle FA metabolism (17, 18). We found that loss of CD36 in CMs did not alter circulating levels of FFAs or glucose (Figure 3, A and B). Therefore, loss
of CD36 only in ECs reproduced many of the overall metabolic
effects seen with total-body CD36 KO.
Postprandial TG levels in response to fat intake were higher in
EC-Cd36 –/– mice. Plasma TG levels 2, 4, and 6 hours after olive oil
gavage were higher in EC-Cd36 –/– mice than in Cd36fl/fl mice (Figure 3C). We detected a greater than 2-fold increase in the AUC for
TG clearance (AUCTG) in EC-Cd36 –/– mice (Figure 3C), suggesting
that EC CD36 is involved in the rapid clearance of circulating TGs.
In contrast, loss of CM CD36 did not alter TG excursion (Figure
3C). Slower postprandial TG clearance is characteristic of total
jci.org   Volume 128   Number 10   October 2018
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Figure 2. Immunocytochemistry and immunofluorescence staining of heart tissue and isolated ECs and CMs. (A) CD36 staining of heart tissue from
Cd36fl/fl, EC-Cd36–/–, and CM-Cd36–/– mice (top) and higher-magnification images of CD36 staining of vascular endothelium and CMs (bottom). Original
magnification, ×40 (top) and ×400 (bottom). (B) Cd36fl/fl and EC-Cd36–/– heart sections were double stained with anti-CD31 (green) and anti-CD36 (red)
antibodies. Scale bars: 5 μm. (C) Isolated CMs from Cd36fl/fl, EC-Cd36–/–, and CM-Cd36–/– mouse hearts stained with anti-CD36 antibody. Scale bars: 25 μm.
(D) Isolated ECs from Cd36fl/fl and EC-Cd36–/– mice stained with anti–VE-cadherin (green) and anti-CD36 (red) antibodies. Original magnification, ×60.

CD36 deficiency in mice (13) and humans (19) and may reflect
greater product inhibition of lipoprotein lipase (LpL) by FFAs.
Glucose levels and insulin sensitivity are altered by loss of CD36
in ECs. EC-Cd36 –/– mice had decreased 16-hour fasting glucose
levels and an improved oral glucose tolerance test (OGTT) (Figure 3D), as was previously found in total Cd36 KOs (20). The AUC
for OGTT (AUCOGTT) for EC-Cd36 –/– mice was 24% lower than for
Cd36fl/fl mice (Figure 3D). Insulin tolerance tests (ITTs) in 2-hour–
fasted mice showed that the more rapid glucose removal was due
to greater insulin sensitivity (Figure 3E).
We generated a second endothelial KO line by crossing Cd36fl/fl
mice with VE-cadherin-Cre (VE-Cd36–/–) mice. In this model, plasma glucose levels were decreased, while FFAs were increased, similar to the effects seen in Tie2-Cre EC-Cd36 –/– mice (Supplemental
Figure 4, A and B).
To confirm that the changes in FFA and glucose levels were not
due to off-target CD36 deletion, we created myeloid CD36-KO mice
using the LysM-Cre transgene. The deletion did not reduce glucose
or increase circulating FFA levels (Supplemental Figure 5, A and B).
CD36 deletion in ECs improves glucose homeostasis and insulin
sensitivity in high-fat diet–fed mice. We next determined whether EC-CD36 loss affected FFAs and glucose in high-fat diet–fed
4332
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(HFD-fed) mice. EC CD36 deletion did not change BWs compared with those of controls (Figure 4A). As with chow, HFD-fed
EC-Cd36 –/– mice had higher circulating FFA levels (Figure 4B).
These mice also had higher plasma TC and TG levels (Figure 4,
C and D) due to increases in both LDL and HDL cholesterol (Supplemental Figure 5C). Total-body Cd36 –/– mice fed a HFD had
improved insulin sensitivity (20). HFD-fed EC-Cd36 –/– mice had
lower glucose and insulin concentrations (Figure 4, E and F) and
improved OGTTs (Figure 4G) and ITTs (Figure 4H). Because
we had seen such prominent changes in gene expression in the
heart, we assessed insulin signaling after a fasting/feeding episode. After fasting and refeeding, EC-Cd36 –/– hearts had greatly
increased phosphorylation of AKT and the ribosomal protein S6
at S240/244, both of which are downstream targets of insulin
signaling (Figures 4I), whereas heart insulin receptor (IR) phosphorylation did not change. To further assess insulin sensitivity,
we obtained muscle, liver, and WAT from mice after insulin injection. In EC-Cd36 –/– liver, we found that phosphorylated IR (p-IR)
was significantly increased (Figure 4J). Deletion of Cd36 in ECs
did not change IR, AKT, or S6 protein levels in skeletal muscle
or WAT (Figure 4K and Supplemental Figure 5D). To test whether improved insulin sensitivity in HFD-fed EC-Cd36 –/– mice was

The Journal of Clinical Investigation  
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Figure 3. EC-Cd36–/– mice have increased FFA and postprandial TG levels but improved glucose metabolism. (A) Plasma FFAs in 4-month-old male
mice fasted for 16 hours (n = 6–8). (B) Plasma glucose levels (n = 6–7) in Cd36fl/fl, EC-Cd36–/–, and CM-Cd36–/– mice. (C) Postprandial TG response in Cd36fl/fl,
EC-Cd36–/–, and CM-Cd36–/– mice. Plasma TG concentrations were measured 0, 2, 4, and 6 hours after intragastric administration of olive oil (n = 5–7). Also
shown is the AUC for postprandial TG levels. (D) Four-month-old male mice (n = 4–8) were fasted for 16 hours before oral glucose administration. Tail blood
was collected for glucose measurements at 0, 15, 30, 60, and 120 minutes after glucose administration. Also shown is the AUC of glucose excursions. (E)
For ITTs, mice were fasted for 4 hours and given 0.75 U/kg BW insulin i.p. Tail blood samples were obtained before insulin administration (t0) and then 15,
30, 45, 60, and 120 minutes after insulin injection (n = 4–5 mice; data are representative of 2 independent experiments). Data represent the mean ± SD.
*P < 0.05, #P < 0.01, and §P < 0.001 compared with Cd36fl/fl controls; 1-way ANOVA with Dunnett’s multiple comparisons test.

related to reduced ceramides and diacylglycerols (DAGs), we
assessed the distribution of these lipids in skeletal muscle and
heart. Long-chain ceramides (Cer18:1) in the heart and very longchain ceramides (Cer22:0, Cer24:0, and Cer24:1) in both heart
and skeletal muscle were significantly reduced in EC-Cd36 –/– mice
(Figure 4, L and M). Cardiac and muscular DAGs were not altered
(Supplemental Figure 5, E and F). Thus, EC-CD36 deletion protected mice from HFD-induced insulin resistance and was associated with reduced ceramide species.
CD36 deletion in ECs reduces LCFA uptake by heart, skeletal muscle, and BAT. To test directly whether loss of CD36 in ECs reduces
the uptake of LCFAs in vivo, we injected [3H]oleic acid and [14C]
hexanoic acid, which is not recognized by CD36, into 16-hour–
fasted male mice and assessed their tissue uptake. Compared with
Cd36fl/fl and CM-Cd36 –/– mice, we observed that EC-Cd36 –/– mice
had significantly delayed plasma clearance of oleic acid (Figure
5A) and a greater than 50% reduction in oleate uptake by heart,
quadriceps muscle, and BAT (Figure 5B). In contrast, uptake
by liver, lung, and kidney was unchanged. We observed similar
results of reduced plasma LCFA clearance and uptake into heart
and BAT in female mice (Supplemental Figure 6, A and B). However, skeletal muscle uptake was not altered in female mice. The lack

of significant changes in skeletal muscle uptake in the female mice
are consistent with the known sex differences in skeletal muscle
lipid metabolism (21). The signal in WAT was low, and uptake differences were not significant. Hexanoic acid plasma removal and
uptake into tissues were similar in mice of all 3 genotypes (Figure
5, C and D). These data show that EC-CD36 is required for optimal
LCFA uptake by the heart, skeletal muscle, and BAT.
We also assessed acute LCFA accumulation in the heart and
other tissues in real time using [11C]palmitate PET. As found with
radiolabeled tracers, EC-Cd36 –/– mouse hearts had a marked
reduction in tracer uptake compared with Cd36fl/fl and CM-Cd36 –/–
mouse hearts (Figure 5E). We also detected significantly reduced
FA uptake by skeletal muscle and BAT in EC-Cd36 –/– mice (Figure
5F). In contrast to the reduction noted with EC deletion, neither
[3H]oleic acid (Figure 5B) nor PET scan assessment of heart palmitate uptake (Figure 5E, right) in CM-Cd36 –/– mice differed from
what was observed in Cd36fl/fl mice. Neither deletion affected palmitate uptake into the liver (Supplemental Figure 6C).
CD36 deletion in ECs increases glucose uptake by heart, skeletal muscle, and BAT. Fasting reduces glucose uptake by heart
and muscle, an adaptation impaired by total CD36 deficiency in
humans (22) and mice (4, 9). We examined tissue uptake of [18F]
jci.org   Volume 128   Number 10   October 2018
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Figure 4. EC-Cd36–/– improves glucose homeostasis and increases insulin sensitivity in 6-month-old male mice fed a HFD for 4 months. (A–E) BW, plasma lipids, and glucose after a 16-hour fast. (F) Plasma insulin after a 16-hour fast followed by a 4-hour refeeding period. P value was determined by 1-way
ANOVA. (G) For GTTs, male mice fasted for 16 hours were given oral glucose, and tail blood samples were collected for glucose measurements at 0, 15, 30,
60, and 120 minutes. Also shown is the AUC of glucose excursions. (H) For ITTs, mice fasted for 4 hours were given 0.75 U/kg BW insulin i.p. Tail blood
samples were obtained at t0 and then 15, 30, 45, 60 and 120 minutes after insulin administration. (I) Activity of IR, AKT, and S6 in Cd36fl/fl and EC-Cd36–/–
mice 20 minutes after insulin injection, with densitometric analysis of (I) heart, (J) liver, and (K) skeletal muscle tissue. (L and M) Individual ceramide (Cer)
species in heart (n = 5) and muscle (n = 9–10). Data represent the mean ± SD. *P < 0.05 and #P < 0.01 compared with Cd36fl/fl controls; 1-way ANOVA with
Dunnett’s multiple comparisons test (A–E and G–M).

deoxyglucose (FDG]DG) using PET in 16-hour–fasted mice and
found that glucose uptake increased in heart, muscle, and WAT of
EC-Cd36 –/– mice compared with controls (Figure 5G). In contrast,
tissues of CM-Cd36 –/– mice showed no changes in glucose uptake
(Supplemental Figure 6D). These data show that EC CD36 regulates the fasting-induced metabolic shift by tissues, which spares
glucose use and increases reliance on FAs.
CD36 deletion in either ECs or CMs reduces heart lipid storage.
The heart normally increases its lipid stores during fasting. Studies in Cd36 –/– mice suggest that CD36 is required for this adaptation (4, 9, 10, 23). We fasted mice for 16 hours and assessed lipid droplet accumulation using BODIPY dye. We found that lipid
4334
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droplet accumulation was significantly reduced in EC-Cd36 –/–
hearts (Figure 6A). Lipid droplet numbers were significantly
decreased in both EC-Cd36 –/– and CM-Cd36 –/– hearts, as assessed
by electron microscopy (Figure 6, B and C), while heart morphology appeared normal. Direct measurements of heart TGs
showed that hearts from EC-Cd36 –/– mice had a 49% reduction
in TGs and CM-Cd36 –/– mice had a 53% reduction (Figure 6D).
Thus, CD36 deletion in either ECs or CMs reduced heart lipid
accumulation. We also observed decreased cardiac lipid accumulation in VE-Cd36 –/– mice (Supplemental Figure 7, A and B).
As might be expected with reduced lipid uptake into peripheral
tissues, EC-Cd36 –/– mice had increased liver TG content (Supple-

The Journal of Clinical Investigation  
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Figure 5. EC-Cd36–/– mice have reduced tissue LCFA uptake during fasting. (A–D) Uptake of oleic and hexanoic acids in EC-Cd36–/– mice. Four-month-old
mice were fasted for sixteen hours and given a tail i.v. injection of [3H]oleic acid and [14C]hexanoic acid. (A) Plasma 3H radioactivity in Cd36fl/fl, EC-Cd36–/–, and
CM-Cd36–/– mice (n = 5–6) measured at the indicated time points after injection. Scale bars: 50 μm. (B) 3H content of different tissues, (C) plasma 14C radioactivity, and (D) 14C content of different tissues. (E) Real-time [11C]palmitic acid uptake into heart, and (F) tissue [11C]palmitic acid uptake in Cd36fl/fl and EC–Cd36–/–
male mice (n = 4). (G) Tissue FDG uptake in Cd36fl/fl and EC–Cd36–/– mice (n = 4) derived from summing the uptake kinetics up to 60 minutes after tracer administration. Also shown are representative scans of FDG accumulation at 60 minutes in the hearts of control and EC-Cd36–/– 16-hour–fasted mice. Max, maximum.
Data represent the mean ± SD. *P < 0.05, #P < 0.01, and §P < 0.001 compared with Cd36fl/fl controls; 1-way ANOVA with Dunnett’s multiple comparisons test.

mental Figure 7C). The increase in heart TGs was associated with
an increase in diacylglycerol acyl transferase 1 (DGAT1) (Supplemental Figure 1E), a compensation that might have prevented the
accumulation of lipids that interfere with insulin signaling (24, 25).
EC or CM CD36 deletion reduces the expression of FA metabolism heart genes and differentially alters glucose metabolism genes.
We performed RNA sequencing (RNA-seq) to gain an unbiased
global view of transcript expression in EC-Cd36 –/– and CM-Cd36 –/–
mouse hearts. Gene heatmap analysis (Figure 7) showed marked
expression changes in hearts from both groups of mice. Expression of glucose metabolism and glucose signaling genes showed
differential regulation. In EC-Cd36 –/– mouse hearts, we detected
increases in mRNA levels of genes mediating glucose uptake and
oxidation such as Slc2a1 (Glut1), Slc2a4 (Glut4), Pcx (pyruvate
carboxylase), Hk2 (hexokinase 2), Gck (glucokinase), and Pfkfb2 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2).
Decreased expression of Pdk4 (pyruvate dehydrogenase kinase 4),
which inhibits pyruvate conversion to acetyl-CoA, was consistent
with enhanced glucose utilization. These changes were associated
with increased expression of insulin signaling pathway genes such
as Irs1 (insulin receptor substrate 1), Pten (phosphatase and tensin
homolog), Pik3r1 (phosphoinositide 3 kinase regulatory subunit 1,
also known as p85), Foxo1 (Fox protein 01), and Mapk4 (MAPK4).
In CM-Cd36 –/– mice, in contrast to EC-Cd36 –/– mice, we detected reduced cardiac expression of glucose metabolism genes, while
expression of genes for insulin signaling was not affected. These
data suggest that CD36 deletion in ECs enhances the expression

of genes related to glucose utilization and insulin action, while the
effect of the deletion in CMs is opposite or neutral.
PPARs, especially PPARα, modulate LCFA oxidation in the
heart. Ppara mRNA levels increased in EC-Cd36 –/– hearts (Figure
7, red arrow), while levels of PPARγ and PPARβ, and PPARδ were
unchanged in both EC- and CM-KO hearts. However, expression of FA metabolism genes including many PPARα targets was
decreased in both groups of mice. For example, expression of
Slc27a1 (FA transport protein 1), Cpt1a (carnitine palmitoyl transferase 1a), Cpt2, Acot2 (acyl CoA thioesterase 2), Acadl (acyl CoA
hydrogenase 1), Acadm (medium chain ACAD), and Hsd17b4
(hydroxysteroid 17 β dehydrogenase 4) decreased markedly in
EC-Cd36 –/– and CM-Cd36 –/– hearts. In both groups, Slc25a20 (carnitine acyl carnitine translocase, also known as Cact), which mediates the transport of acylcarnitines from the cytosol to the mitochondrial matrix, was reduced (Figure 7). These changes indicate
that CD36 in both ECs and CMs regulates tissue FA metabolism.
In CM-Cd36 –/– hearts, these changes were consistent with the
effects of CD36 on FA oxidation, as documented in an overexpression mouse model (26) and in tissue culture experiments (27).
Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses of insulin- and PPAR-activated pathways highlighted the
enhanced insulin signaling detected in EC-Cd36–/– hearts, with
increased expression of major regulators of GLUT4 translocation,
lipogenesis, and glycogenesis (Figure 8A). This was not apparent
in CM-Cd36–/– hearts. We noted diminished expression of major
PPAR targets in EC-Cd36–/– hearts (Figure 8B). Expression levels
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Figure 6. CD36 deletion in ECs or CMs reduces heart
lipid storage during fasting. (A) Heart tissue sections
from Cd36fl/fl, EC-Cd36–/–, and CM-Cd36–/– mice were
stained with BODIPY 493/503. Scale bars: 50 μm. (B)
Electron micrographs (original magnification ×3,400,
top row, and ×15,000, bottom row) of myocardial tissue
showing a significant decrease in lipid droplets within
the sarcoplasm of CMs from EC-Cd36–/– and CM-Cd36–/–
mice. Yellow arrows indicate lipid droplets. (C) Lipid
droplet numbers in heart tissue sections (n = 4) from
Cd36fl/fl, EC-Cd36–/–, and CM-Cd36–/– mice (expressed
per 100 μm2). (D) Heart TG content in Cd36fl/fl (n = 10),
EC-Cd36–/– (n = 6), and CM-Cd36–/– mice (n = 3). Data
represent the mean ± SD. *P < 0.05, #P < 0.01, and
§
P < 0.001 compared with Cd36fl/fl controls; 1-way
ANOVA with Dunnett’s multiple comparisons test.

of several PPAR and insulin signaling pathway genes such as Pparα
and Glut1 were increased in hearts of EC-Cd36–/– mice, while Fas
and Ampk expression levels were decreased (Figure 8C). Hearts
from CM-Cd36–/– mice, like those from germline Cd36–/– mice, had
higher Ampk mRNA levels (Supplemental Figure 8A) (10, 23). This
contrasted with lower Ampk levels in hearts from EC-Cd36–/– mice
(Figure 8A), perhaps reflecting greater glucose uptake. However, like
in EC-Cd36–/– hearts, we found that expression levels of major PPAR
target genes in CM-Cd36–/– hearts were decreased (Supplemental
Figure 8B). These data were confirmed by qRT-PCR (Figure 8C). We
also observed decreased expression of Pdk4, Cpt1, and Aox mRNA in
female EC-Cd36–/– mouse hearts (Supplemental Figure 8C).

Discussion

Delivery of LCFA to parenchymal cells in tissues that do not have
fenestrated capillaries involves transfer from the circulation to
parenchymal cells. This movement of LCFAs requires their transfer
either through or around ECs. CD36 has been reported to mediate
LFCA uptake into muscle and adipose tissues (11, 12) and LCFA
accumulation in CMs (28) and other cells (29), but its role in ECs
had not been directly studied. We show that ECs robustly express
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CD36 and that EC-specific CD36 deletion reduces acute LCFA
uptake into heart and other tissues. Moreover, EC-Cd36 –/– mice
have increased insulin sensitivity and lack myocardial lipid droplet accumulation with fasting. Reductions in ceramides might have
contributed to the improved insulin sensitivity. The reduction of
FA uptake into BAT might have important implications for thermogenesis. In this regard, Bartelt et al. (30) have shown that both LpL
and CD36 affect BAT uptake of FAs during cold exposure.
Several reports have suggested that ECs are a major regulator
of tissue LCFA metabolism. These reports did not directly investigate EC CD36, but some included indirect evidence that is consistent with our current findings. Deletion of EC PPARγ increased circulating LCFAs (31) and reduced expression of several PPARγ gene
targets in ECs, including CD36. Meox2/Tcf15 heterodimer transcription factors (TFs) in ECs have been reported to regulate FA
transfer across the cardiac capillary endothelium (32) and to affect
the expression of FA-metabolizing genes, including Cd36. Deletion of EC VEGF-B (33) was reported to cause changes in EC LCFA
uptake as a result of transcriptional regulation of vascular-specific
FA transport proteins 3 and 4, but this was not confirmed by others
(34). A recent report showed that a metabolite of branch chain ami-
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on the cell surface and FA uptake by
ECs and adipocytes (36).
Robust CD36 expression in capillary
ECs (37) is found in tissues that are most
active in circulating LCFA extraction
and that also express LpL and its EC
anchoring protein glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 (GPIHBP1). This
expression pattern suggests that CD36
is important in LCFA trafficking across
smaller blood vessels and capillaries,
where most nutrient uptake occurs. ECs
are not major sites of FA oxidation, so
CD36 in capillaries is likely to be more
important for LCFA transport than for
LCFA-derived ATP production. This
conclusion is supported by our data
showing that lack of CD36 expression
does not change EC mRNA levels of FA
or glucose metabolism genes.
The lack of lipid droplet accumulation with EC and CM CD36 deletion
shows that CD36 expression at both
sites is required for optimal delivery
of LCFAs to the heart. The defect in
uptake into EC-Cd36 –/– mouse hearts
was evident using 2 types of tracer
kinetic studies: radiolabeled LCFA and
[11C]palmitate PET. Both of these techniques assess the rapid accumulation
of LCFAs and, for this reason, might
have failed to show a defect in LCFA
uptake into CM-Cd36 –/– hearts; CM
CD36 is well established as a mediator of LCFA accumulation in cultured
CMs (38, 39) and as a provider of substrates required for the response to
acute afterload (40). In addition, our
studies highlight important differences in the contribution of ECs versus
CMs to FA metabolism in the heart,
and additional studies are needed to
understand the mechanisms underlying these differences.
Loss of EC CD36 led to improved
insulin action and glucose disposal,
which we demonstrated using cardiac
Figure 7. Heart tissue mRNA expression in mice with EC or CM CD36 deletion. Clustered heatmaps from
gene expression, OGTTs, and ITTs.
RNA-seq data showing differential expression profiles for Cd36fl/fl, EC-Cd36–/–, and CM-Cd36–/– mice. Red
These effects were confirmed in HFDindicates overabundant expression; blue indicates underabundant expression.
fed mice. Improvements in OGTTs and
ITTs were similar to those observed
with PPARα (41) or GLUT4 deletion (42). In addition, circulating
no acids modulated both LCFA movement across ECs and insulin
glucose levels were reduced, as was found with some (43), but not
sensitivity (35). Interestingly, the molecular mechanisms mediatall (44), genetic mutations that reduce FA oxidation. FDG PET
ing FA uptake by EC CD36 might differ among tissues. Salameh
showed increased glucose uptake into heart, skeletal muscle, and
et al. recently reported on a mechanism specific to adipocytes,
WAT with EC CD36 deletion. CM-Cd36 –/– mice did not have simdescribing a prohibitin–annexin A2 complex that increases CD36
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Figure 8. KEGG analysis of insulin signaling and PPAR pathways. KEGG
analysis of (A) insulin and (B) PPAR signaling pathways. (C) qRT-PCR
analysis of heart mRNA in Cd36fl/fl, EC-Cd36–/–, and CM-Cd36–/– mice (n =
5–7). Data are shown as the mean ± SD. *P < 0.05 compared with Cd36fl/fl
controls; 1-way ANOVA with Dunnett’s multiple comparisons test.

ilar improvements in insulin action or glucose metabolism, and,
instead, hearts from these mice had downregulated expression
of some glucose uptake genes, opposite to what would be expected with reduced lipid uptake. These changes might reflect myocyte-autonomous actions of CD36 that regulate insulin signaling
(45). These separate effects on parenchymal biology could explain
the propensity to develop insulin resistance in humans with CD36
mutations (46).
In humans, CD36 deficiency has a prevalence of 0.3% to
9%, with a higher incidence in Asian and African populations.
Individuals with complete CD36 deficiency have higher serum
levels of fasting TGs (47) and chylomicron remnants (19). These
lipid abnormalities likely reflect defective tissue FA metabolism,
as CD36-deficient individuals show markedly reduced LCFA
uptake by the heart (14, 22) and have enhanced myocardial glucose uptake (22).
In summary, our data show that ECs are major sites of regulation of LCFA uptake and, in turn, tissue lipid metabolism
and insulin sensitivity. By regulating heart and skeletal muscle
FA delivery and glucose utilization, EC CD36 is a major factor
affecting tissue fuel selection and systemic metabolism. Whether
EC CD36 actions are beneficial for normal or diseased hearts is
uncertain (48–50) and probably depends on the physiologic situation. Reduction of LCFA uptake leads to impaired energy production during fasting or exercise, but also protects against excess
lipid accumulation (lipotoxicity) (51) and improve glucose utilization during hypoxia (52). The vascular endothelium represents an
important and accessible therapeutic target (53), and our findings
suggest that targeting EC CD36 could be a means to influence tissue FA uptake and prevent or treat a variety of diseases caused by
abnormal lipid utilization.

Methods

Generation of Cd36fl/fl mice. A Lox (L83) site and Frt-Neo-Frt-LoxP
(FNFL) cassette were engineered to flank a 1.7-kb sequence with
exons 3 and 4 of CD36 to generate a floxed/Neo CD36 allele on a
bacterial artificial chromosome (BAC). A gene-targeting vector was
created by retrieving the 2-kb short homology arm (5′ to L83), the
floxed sequence containing exons 3 and 4, the FNFL cassette, and the
10-kb-long homology arm (end of FNFL to 3′) into a plasmid vector
carrying a diphtheria toxin α (DTA) chain negative selection marker.
The FNFL cassette conferred G418 resistance during gene targeting in KV1 (129B6 hybrid) embryonic stem (ES) cells, and the DTA
cassette provided autonomous negative selection to reduce random
integration. Identified targeted ES cells were injected into C57BL/6
blastocysts to generate chimeric mice. Male chimeras were bred
with homozygous ACTB (Flpe/Flpe) C57BL/6 females to remove the
neomycin cassette and transmit the floxed CD36 allele (Flpe recombinase). The mice were then crosLoxsed with Tie2-Cre and MHCCre mice (C57BL/6) to generate EC-Cd36 –/– and CM-Cd36 –/– mice
and with LysM-Cre mice to create myeloid cell deficiencies. Found-
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er Cd36fl/fl mice were identified by tail genomic DNA analysis with
primer 1F specific to the upstream LoxP locus (5′-ATTGGCATCTGTGTAGCGCTCTTGGC-3′) and primer 1R (5′-TGCTACTATGCACTCCATGCAGGC-3′), an antisense specific to the downstream
LoxP locus. CD36 deletion in EC-Cd36 –/– hearts was confirmed by
PCR of heart tissue DNA and mRNA with primers 2 and 3 (Supplemental Table 1), respectively. Mice were maintained under a constant
light-dark cycle (light from 7:00 am to 7:00 pm) and received either
a standard diet (catalog 5053, LabDiet) or a HFD containing 65% fat
(catalog D12492, Research Diets).
Human tissues. Normal human heart tissues were obtained from
the Department of Surgery at Columbia University Medical Center.
Western blot analysis. Total proteins were obtained from fresh heart
tissues of 4- to 6-month-old EC-Cd36–/– and CM-Cd36–/– mice and littermate controls using a RIPA Kit (Santa Cruz Biotechnology). Proteins
(30 μg), separated by Western blotting, were probed for CD36 (catalog
AF2519, R&D Systems, 1:200 dilution) and α-tubulin (catalog ab7291,
Abcam, 1:5,000 dilution) as a control. Antibodies against Akt (Ab 9272),
p-Akt (S473) (mAb 4060), S6 (mAb 2217), p-S6 (S240/244) (Ab 2215), IR
(mAb 3025), p-IR (mAb 3024), and β-actin (mAb 4970) were obtained
from Cell Signaling Technology. Signals were quantified by densitometry using the Odyssey Fc Imaging System (LI-COR Biotechnology).
Heart and plasma lipids. Blood from fasted (4 or 16 h) mice was
collected from the retro-orbital plexus. Plasma TC, TGs, and FFA were
measured enzymatically using an Infinity Kit (Thermo Electron Corp.)
and a NEFA C Kit (Wako). To measure heart TGs, hearts were perfused
with PBS and homogenized at 4°C in 1 M NaCl buffer with lipase inhibitors. Lipids were extracted from heart tissues (50 mg) according to a
modified Folch method (54). The dried lipids were solubilized in PBS
with 2% Triton X-100, and TG levels were measured using an Infinity
TG Kit (Thermo Electron, Thermo Fisher Scientific.).
IHC. Human and mouse cardiac ventricular specimens were
fixed in 10% buffered formaldehyde and embedded in paraffin, and
5-μm-thick microtomic sections were stained with a 1:100 dilution of
mouse and human CD36 antibodies (AF2519, AF1955; R&D Systems).
After washing, sections were incubated (2 h at room temperature) with
a biotinylated rabbit anti-goat IgG antibody. Staining specificity was
tested by omission of primary antibodies.
Immunofluorescence staining. Cardiac ventricular tissues from
4-month-old male mice were embedded in Tissue-Tek OCT Compound (Sakura). Frozen sections (5-μm thickness) were fixed in 10%
formalin for 30 minutes, washed 3 times in PBS, and blocked for 1 hour
in 1% BSA-PBS at room temperature. The fixed sections were incubated (2 h, room temperature) with a 1:100 dilution of either mouse CD36
(catalog AF2519, R&D Systems) or CD31 (catalog 102514, BioLegend)
antibody followed by washing and incubations (1 h) with a secondary
antibody (1 : 500 dilution) coupled to Alexa Fluor 488 or 594 (Invitrogen, Thermo Fisher Scientific). Washed sections were then stained with
ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific), and digital images were obtained with a Leica confocal microscope.
Isolated ECs were fixed with 4% PFA, permeabilized with 0.2% Triton
X-100, and blocked with donkey serum. Then, cells were incubated
with anti–VE-cadherin (ab33168, Abcam) and CD36 (AF2519, R&D
Systems) antibodies followed by secondary antibodies conjugated with
Alexa Fluor 488 and Alexa Fluor 594. Nuclei were visualized with DAPI.
Imaging was performed using a Nikon Eclipse inverted microscope at
×60 magnification.
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Lipoprotein isolation. Plasma was pooled from EC-Cd36 –/– mice
fed chow or a HFD. Lipoprotein fractions were separated by a previously described method (55).
OGTT. Cd36fl/fl, EC-Cd36 –/–, and CM-Cd36 –/– mice fasted for 16
hours were given 2 g glucose/kg body mass intragastrically. Tail blood
samples were collected and glucose measured 0, 15, 30, 60, and 120
minutes after gavage.
Plasma insulin measurements. Cd36fl/fl and EC-Cd36 –/– were fasted for 16 hours and refed for 2 hours. Blood was collected from the
retro-orbital plexus, and plasma insulin levels were measured using a
mouse ultrasensitive insulin ELISA kit (ALPCO).
ITTs. Mice were fasted for 4 hours and then given human insulin
(Eli Lilly, 0.75 U/kg BW) intraperitoneally. Tail blood was obtained 0,
15, 30, 45, 60, and 120 minutes after insulin injection.
Insulin signaling test. For insulin-induced changes, 2 different methods were used to assess insulin signaling in 3-month-old male mice fed
a HFD for 6 weeks using. Changes in the heart were most evident when
assessed after fasting (16 h) followed by refeeding (2 h), after which
hearts were harvested and used for Western blot analysis. Other tissues
were studied after i.p. insulin injection (0.50 U/kg BW human insulin, Eli
Lilly). Skeletal muscle, liver, and WAT were harvested 20 minutes after
insulin injection and then used for Western blotting.
Lipid droplet staining. Cardiac ventricular tissues from 4-monthold male mice were embedded in Tissue-Tek OCT Compound (Sakura). Frozen sections of myocardium (5-μm thickness) were fixed in 10%
formalin for 30 minutes at room temperature and then washed 3 times
in PBS. The fixed sections were then incubated with 4 μM BODIPY
493/503 dye (catalog D3922, Invitrogen, Thermo Fisher Scientific) for
30 minutes at room temperature. After washing, sections were stained
with ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific) and covered with glass coverslips (VWR, Avantor). The digital
images were obtained with a Leica confocal microscope.
Postprandial lipemia. After a 16-hour fast, mice maintained on a chow
diet received an intragastric bolus of 0.3 ml olive oil. Tail blood samples
were collected before and 2, 4, and 6 hours after gavage. Plasma TG concentration was assayed with an Infinity Kit (Thermo Fisher Scientific).
EC isolation. Lungs harvested from Cd36fl/fl and EC-Cd36 –/–
mice (Tie2-Cre) were minced and enzymatically digested in MACS
C-tube (Miltenyi Biotec). Cells were centrifuged, resuspended in
PEB buffer (1× PBS, 0.5% BSA, 2 mM EDTA), blocked with FcR
blocking reagent (Miltenyi Biotec), and then incubated with CD31
conjugated microbeads for 15 minutes at 4°C. The cell suspension
was passed through a MACS separation column, the column was
washed with PEB buffer (3×), and the cells eluted and plated onto
gelatin-coated coverslips in 6-well plates.
Heart suborgan fractionation. Cardiac cells were dissociated as
described previously using Liberase TH (0.125 U/ml) (MilliporeSigma)
(56). The cell suspension was filtered through a 100-μm strainer and
centrifuged at 50 g for 5 minutes. CMs were pelleted and subjected to
Percoll density gradient centrifugation (1,200 g for 30 min) for RNA
and protein isolation. Non-CMs in the supernatant were centrifuged
at 500 g (10 min) and prepared for FACS. RBC in non-CMs were
lysed and pellets resuspended in staining buffer (2% FBS/PBS, 2 mM
EDTA, and 100 U/ml RNase inhibitor; catalog M0314L, New England
BioLabs). Incubation with calcein AM (100 nM, room temperature,
30 min) and then with CD45 and CD31 antibodies (catalogs 103114
and 102508, BioLegend) on ice (30 min) was followed by 7-AAD (5
4340
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μg/ml) for an additional 10 minutes before the end of the incubation.
Cells were pelleted, resuspended, filtered (70-μm Flowmi cell strainer), and sorted on a FACSAria Fusion (BD Biosciences). Singlet cells
were gated by forward scatter area (FSC-A) and forward scatter height
(FSC-H). Additional gating of live (calcein AM+7-AAD –) cells was performed. CD45 –CD31+ EC fractions were collected for RNA isolation.
ISH. CD36 mRNA expression was detected in frozen sections via
ISH using probes and the QuantiGene ViewRNA tissue assay (Affymetrix) according to the manufacturer’s instructions. No probe controls
or tissues from Cd36-KO mice were used for negative controls.
LCM. Mouse heart tissues were filled with OCT compound. Polyethylene naphthalate (PEN) membrane glass slides were prepared
for cryosectioning. The tissue block was cryosectioned entirely at
10 μm and stained with H&E for histomorphologic identification of
cardiomyocytes. A Leica DM6000 B microscope was used for cardiomyocyte harvesting. Captured cardiomyocytes were subjected to
RNA purification (ARCTURUS PicoPure RNA Isolation Kit, Applied
Biosystems, Thermo Fisher Scientific) and cDNA amplification (The
Ovation Pico WTA System V2, NuGEN).
Tissue gene expression. Four-month-old mice were fasted for sixteen hours. Total RNA was prepared using a Pure Link Micro-to-Midi Total Purification Kit (Invitrogen, Thermo Fisher Scientific). RNA
(1 μg) was treated with DNase I (Invitrogen, Thermo Fisher Scientific)
for 15 minutes and reverse transcribed using the ThermoScript
RT-PCR Kit (Invitrogen, Thermo Fisher Scientific). An ABI 7700 system (Applied Biosystems, Thermo Fisher Scientific) and SYBR Green
PCR Master Mix (Applied Biosystems, Thermo Fisher Scientific)
were used for qRT-PCR. For analysis, we used Sequence Detection
Software (Applied Biosystems, Thermo Fisher Scientific) and standard curves generated using undiluted and diluted (1:10, 1:100, and
1:1,000) cDNA heart tissue samples. Correlation coefficients were
0.98 or greater. Data were normalized to 18S rRNA.
RNA-seq data analysis. Raw sequencing data were received in
FASTQ format. Read mapping used Tophat 2.0.9 against the mm10
mouse reference genome. The resulting BAM alignment files were
processed using the HTSeq 0.6.1 python framework and respective
mm10 GTF gene annotation (UCSC database). The Bioconductor
package DESeq2 (3.2) was used to identify differentially expressed
genes (DEGs) and for statistical analysis based on a negative binomial distribution model. The resulting values were adjusted using the
Benjamini-Hochberg method for FDR determination. Genes with an
adjusted P value of less than 0.05 were determined to be differentially
expressed, and KEGG Analysis was performed to identify top canonical pathways being altered. RNA-seq data were deposited in the NCBI’s
Gene Expression Omnibus (GEO) database (GEO GSE116350).
Electron microscopy. Left ventricles from 16-hour–fasted 4-monthold male mice were fixed with 2.5% glutaraldehyde and 2% paraformaldehyde in 0.1M sodium cacodylate buffer (pH 7.2) for 2 hours and
then postfixed with 1% osmium tetroxide (1.5 h at room temperature),
processed, and embedded in EMbed 812 (Electron Microscopy Sciences). Ultrathin sections (60-nm) were cut (Leica UC6 microtome),
mounted onto 200 mesh copper grids, and stained with uranyl acetate
and lead citrate. Stained grids were examined with a Philips CM-12
electron microscope and photographed with a Gatan (4 k × 2.7 k) digital camera. Lipid droplets were counted in random 100-μm2 areas.
Uptake of [3H]oleic acid and [14C]hexanoic acid. Cd36fl/fl, EC-Cd36 –/–,
and CM-Cd36 –/– mice (4-month-old, 16-hour–fasted) were injected i.v.
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with 100 μl PBS containing 1 × 106 dpm of [3H]oleic acid and 1 × 106
of [14C]hexanoic acid (PerkinElmer). Mouse plasma volume was estimated as 0.55 ml/kg BW (57). Plasma radioactive concentration was
calculated by BW (mg) × (0.55 ml/1,000 mg) × 106 (dpm). Blood was
collected 0, 30, 120, and 300 seconds after injection for radioactive
counts (10 μl plasma). The heart vasculature was perfused with 10
ml PBS via cardiac puncture 5 minutes after injection. Tissues were
excised and accumulated radioactivity measured. Tissue oleic and
hexanoic acid uptake was adjusted by plasma radioactivity at 30 minutes and normalized to that of littermate controls.
PET studies. Differences in FA metabolism and FDG were evaluated with PET imaging of 4- to 5-month-old 16-hour–fasted mice using
[11C]palmitate and [18F]DG as described previously (58). The uptake
and transport of tracer were visualized and quantified by summing the
uptake kinetics up to 60 minutes after tracer administration. All images and corresponding data were normalized to the dose and weight
of the animal and presented as the standardized uptake value (SUV =
activity × weight/injected dose).
Statistics. Results are expressed as the mean ± SD. Significant differences between groups were determined by an ANOVA t test or a
1-way ANOVA multiple comparisons test. The AUC value was evaluated using the trapezoid method. A P value of less than 0.05 was considered significant.
Study approval. The IRBs of Columbia University and New York University Medical Center approved all study protocols. Generation of the
mice and all metabolic and genetic studies were reviewed and approved
by the IACUCs of New York University and Washington University.
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